Search Result

Results for "

statins

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Antibiotic (2) Apolipoprotein (1) Apoptosis (3) Autophagy (3) Bacterial (2) Calcineurin (1) CETP (1) Drug Metabolite (3) Endogenous Metabolite (4) Ferroptosis (3) HMG-CoA Reductase (HMGCR) (8) IGF-1R (1) Isotope-Labeled Compounds (3) LDLR (1) LPL Receptor (1) NO Synthase (2) Potassium Channel (2) Ras (1) Reference Standards (3) Virus Protease (1)
By Research Areas:	Cancer (6) Cardiovascular Disease (9) Infection (2) Inflammation/Immunology (4) Metabolic Disease (9) Neurological Disease (2)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-112490

Atorvastatin calcium hydrate Maximum Cited Publications 65 Publications Verification	HMG-CoA Reductase (HMGCR)	Cardiovascular Disease Others
Atorvastatin calcium salt trihydrate is a drug belonging to the statin class of drugs used to lower blood cholesterol levels. Atorvastatin calcium salt trihydrate has unique chemical properties that make it an effective tool in controlling high levels of low-density lipoprotein (LDL) cholesterol and triglycerides in the body, reducing the risk of heart attack and stroke. Atorvastatin calcium salt trihydrate works by inhibiting HMG-CoA reductase, the enzyme responsible for producing cholesterol in the liver.

HY-17408

Mevastatin Maximum Cited Publications 7 Publications Verification Compactin; ML236B	HMG-CoA Reductase (HMGCR) Bacterial Autophagy Apoptosis Antibiotic	Infection Cardiovascular Disease Neurological Disease Metabolic Disease Cancer
Mevastatin (Compactin) is a first HMG-CoA reductase inhibitor that belongs to the statins class. Mevastatin is a lipid-lowering agent, and induces apoptosis, arrests cancer cells in G₀/G₁ phase. Mevastatin also increases endothelial nitric oxide synthase (eNOS) mRNA and protein levels. Mevastatin has antitumor activity and has the potential for cardiovascular diseases treatment .

HY-109523

Cerivastatin sodium 2 Publications Verification	HMG-CoA Reductase (HMGCR) Ferroptosis	Cardiovascular Disease Cancer
Cerivastatin sodium is a synthetic lipid-lowering agent and a highly potent, well-tolerated and orally active HMG-CoA reductase inhibitor, with a Ki of 1.3 nM/L. Cerivastatin sodium reduces low-density lipoprotein cholesterol levels. Cerivastatin sodium also inhibits proliferation and invasiveness of MDA-MB-231 cells, mainly by RhoA inhibition, and has anti-cancer effect .

HY-107855

DL-Mevalonolactone 1 Publications Verification (±)-Mevalonolactone; Mevalolactone	Endogenous Metabolite	Metabolic Disease Inflammation/Immunology
DL-Mevalonolactone ((±)-Mevalonolactone;Mevalolactone) is the δ-lactone form of mevalonic acid, a precursor in the mevalonate pathway. DL-Mevalonolactone is orally active against HMGCR mutation and statin caused myopathy . DL-Mevalonolactone induces inflammation and oxidative stress response with decreased mitochondrial membrane potential (MMP) and induces mitochondrial swelling ^[2][4].

HY-14925

Lapaquistat 2 Publications Verification T-91485	Endogenous Metabolite Drug Metabolite	Metabolic Disease
Lapaquistat (T-91485), a cholesterol biosynthesis inhibitor, is the active metabolite of Lapaquistat acetate (HY-16274). Lapaquistat can decrease statin-induced myotoxicity in lipid-lowering therapy .

HY-P99284

Dalotuzumab 1 Publications Verification MK-0646; h7C10	IGF-1R Apoptosis	Cancer
Dalotuzumab (MK-0646) is a recombinant humanized monoclonal antibody (IgG1 type) targeting IGF-1R. Dalotuzumab acts by inhibiting IGF-1- and IGF-2-mediated tumor cell proliferation, IGF-1R autophosphorylation, and Akt phosphorylation. Dalotuzumab also induces apoptosis and cycle arrest. Dalotuzumab in combination with other anticancer agents such as statins can enhance the antitumor activity of Dalotuzumab in vitro and in vivo .

HY-114316

HMG499	HMG-CoA Reductase (HMGCR) Autophagy	Cardiovascular Disease Metabolic Disease
HMG499 is a potent and selective HMG-CoA reductase inhibitor with an IC₅₀ of 0.41 μM. HMG499 can prevent statins-induced accumulation of HMGCR, reduce serum cholesterol levels and decrease atherosclerosis .

HY-135700

Mevalonolactone	Calcineurin Ras HMG-CoA Reductase (HMGCR)	Metabolic Disease Inflammation/Immunology
Mevalonolactone is an intermediate metabolite in the eukaryotic mevalonate pathway, serving as the stable δ-lactone form of mevalonate with oral activity. Mevalonolactone exhibits binding affinity for ZNF384 (K_a = 12.6 μM) and inhibitory activity against aconitase (aconitase). Mevalonolactone promotes the nuclear localization of ZNF384 and enhances its binding to the GGPPS promoter. Mevalonolactone induces insulin resistance, disrupts glucose and lipid metabolism, enhances the isoprenylation of K-Ras, and inhibits the activation of the insulin signaling pathway. Mevalonolactone inhibits polypeptide synthesis of HMG-CoA reductase in isolated rat hepatocytes, promotes its degradation, and reduces its enzymatic activity. Mevalonolactone impairs mitochondrial function in rat brains. Mevalonolactone promotes the development of metabolically unhealthy obesity. Mevalonolactone can be used in research related to metabolically abnormal obesity, mevalonic aciduria, HMGCR-related limb-girdle myopathy, and statin-induced myopathy .

HY-129458

Cerivastatin	HMG-CoA Reductase (HMGCR) Ferroptosis	Cardiovascular Disease Cancer
Cerivastatin is a synthetic lipid-lowering agent and a highly potent, well-tolerated and orally active HMG-CoA reductase inhibitor, with a Ki of 1.3 nM/L. Cerivastatin reduces low-density lipoprotein cholesterol levels. Cerivastatin also inhibits proliferation and invasiveness of MDA-MB-231 cells, mainly by RhoA inhibition, and has anti-cancer effect .

HY-17408R

Mevastatin (Standard) Compactin(Standard); ML236B (Standard)	Reference Standards HMG-CoA Reductase (HMGCR) Bacterial Autophagy Apoptosis Antibiotic	Infection Cardiovascular Disease Neurological Disease Metabolic Disease Cancer
Mevastatin (Standard) is the analytical standard of Mevastatin. This product is intended for research and analytical applications. Mevastatin (Compactin) is a first HMG-CoA reductase inhibitor that belongs to the statins class. Mevastatin is a lipid-lowering agent, and induces apoptosis, arrests cancer cells in G₀/G₁ phase. Mevastatin also increases endothelial nitric oxide synthase (eNOS) mRNA and protein levels. Mevastatin has antitumor activity and has the potential for cardiovascular diseases treatment .

HY-107855R

DL-Mevalonolactone (Standard) (±)-Mevalonolactone (Standard); Mevalolactone (Standard)	Endogenous Metabolite Reference Standards	Metabolic Disease Inflammation/Immunology
DL-Mevalonolactone (Standard) is the analytical standard of DL-Mevalonolactone. This product is intended for research and analytical applications. DL-Mevalonolactone ((±)-Mevalonolactone;Mevalolactone) is the δ-lactone form of mevalonic acid, a precursor in the mevalonate pathway. DL-Mevalonolactone is orally active against HMGCR mutation and statin caused myopathy . DL-Mevalonolactone induces inflammation and oxidative stress response with decreased mitochondrial membrane potential (MMP) and induces mitochondrial swelling .

HY-120757

LP-130	Virus Protease	Others
LP-130 is a statin-based inhibitor that is a universal inhibitor with nanomolar inhibitory activity against all tested retroviral proteases. Crystal structure studies of its binding to different retroviral proteases have shown that it can adapt to different active site regions to achieve inhibition.

HY-138166S

Rosuvastatin lactone-d6	Isotope-Labeled Compounds Potassium Channel Drug Metabolite NO Synthase	Cardiovascular Disease
Rosuvastatin lactone-d₆ is the deuterium labeled Rosuvastatin lactone. Rosuvastatin lactone is a metabolite of Rosuvastatin (HY-17504A), a statin lipid-lowering agent and HMG-CoA inhibitor. Rosuvastatin lactone exhibits endothelium-independent and HMG-CoA reductase-independent vasorelaxant activity in rat aortic rings, and its vasorelaxant effect is jointly mediated by NO produced by inducible nitric oxide synthase (iNOS) located in vascular smooth muscle and activation of potassium channels. Rosuvastatin lactone itself has no lipid-lowering effect .

HY-109523S

Cerivastatin-d3 sodium	Ferroptosis HMG-CoA Reductase (HMGCR) Isotope-Labeled Compounds	Cardiovascular Disease Cancer
Cerivastatin-d₃ sodium is deuterated labeled Cerivastatin sodium (HY-109523). Cerivastatin sodium is a synthetic lipid-lowering agent and a highly potent, well-tolerated and orally active HMG-CoA reductase inhibitor, with a Ki of 1.3 nM/L. Cerivastatin sodium reduces low-density lipoprotein cholesterol levels. Cerivastatin sodium also inhibits proliferation and invasiveness of MDA-MB-231 cells, mainly by RhoA inhibition, and has anti-cancer effect .

HY-138166R

Rosuvastatin lactone (Standard)	Reference Standards Potassium Channel Drug Metabolite NO Synthase	Cardiovascular Disease
Rosuvastatin lactone (Standard) is the analytical standard of Rosuvastatin lactone. This product is intended for research and analytical applications. Rosuvastatin lactone is a metabolite of Rosuvastatin (HY-17504A), a statin lipid-lowering agent and HMG-CoA inhibitor. Rosuvastatin lactone exhibits endothelium-independent and HMG-CoA reductase-independent vasorelaxant activity in rat aortic rings, and its vasorelaxant effect is jointly mediated by NO produced by inducible nitric oxide synthase (iNOS) located in vascular smooth muscle and activation of potassium channels. Rosuvastatin lactone itself has no lipid-lowering effect .

HY-W752587

DL-Mevalonolactone-d4 (±)-Mevalonolactone-d₄; Mevalolactone-d₄	Isotope-Labeled Compounds Endogenous Metabolite	Metabolic Disease Inflammation/Immunology
DL-Mevalonolactone-d₄ ( (±)-Mevalonolactone-d₄) is the deuterium labeled DL-Mevalonolactone (HY-107855). DL-Mevalonolactone ((±)-Mevalonolactone;Mevalolactone) is the δ-lactone form of mevalonic acid, a precursor in the mevalonate pathway. DL-Mevalonolactone is orally active against HMGCR mutation and statin caused myopathy . DL-Mevalonolactone induces inflammation and oxidative stress response with decreased mitochondrial membrane potential (MMP) and induces mitochondrial swelling .

HY-18778B

Obicetrapib potassium TA-8995 potassium; DEZ-001 potassium; AMG-899 potassium	Apolipoprotein CETP LPL Receptor LDLR	Metabolic Disease
Obicetrapib (TA-8995; DEZ-001) potassium is an orally active cholesteryl ester transfer protein (CETP) inhibitor. Obicetrapib potassium potently reduces atherogenic lipoproteins (such as LDL-C, ApoB, Lp (a)) and increases HDL-C. Obicetrapib potassium can be used for the research of dyslipidemia and atherosclerotic cardiovascular disease (ASCVD) .

Cat. No.	Product Name	Target	Research Area

HY-120757

LP-130	Virus Protease	Others
LP-130 is a statin-based inhibitor that is a universal inhibitor with nanomolar inhibitory activity against all tested retroviral proteases. Crystal structure studies of its binding to different retroviral proteases have shown that it can adapt to different active site regions to achieve inhibition.

Cat. No.	Product Name	Target	Research Area	Image

HY-P99284

Dalotuzumab 1 Publications Verification MK-0646; h7C10	IGF-1R Apoptosis	Cancer
Dalotuzumab (MK-0646) is a recombinant humanized monoclonal antibody (IgG1 type) targeting IGF-1R. Dalotuzumab acts by inhibiting IGF-1- and IGF-2-mediated tumor cell proliferation, IGF-1R autophosphorylation, and Akt phosphorylation. Dalotuzumab also induces apoptosis and cycle arrest. Dalotuzumab in combination with other anticancer agents such as statins can enhance the antitumor activity of Dalotuzumab in vitro and in vivo .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-17408

Mevastatin Maximum Cited Publications 7 Publications Verification Compactin; ML236B	Infection Cardiovascular Disease Natural Products Microorganisms Neurological Disease Classification of Application Fields Metabolic Disease Disease Research Fields Source Classification	HMG-CoA Reductase (HMGCR) Bacterial Autophagy Apoptosis Antibiotic
Mevastatin (Compactin) is a first HMG-CoA reductase inhibitor that belongs to the statins class. Mevastatin is a lipid-lowering agent, and induces apoptosis, arrests cancer cells in G₀/G₁ phase. Mevastatin also increases endothelial nitric oxide synthase (eNOS) mRNA and protein levels. Mevastatin has antitumor activity and has the potential for cardiovascular diseases treatment .

HY-107855

DL-Mevalonolactone 1 Publications Verification (±)-Mevalonolactone; Mevalolactone	Natural Products Classification of Application Fields Metabolic Disease Endogenous metabolite Inflammation/Immunology Disease Research Fields Source Classification	Endogenous Metabolite
DL-Mevalonolactone ((±)-Mevalonolactone;Mevalolactone) is the δ-lactone form of mevalonic acid, a precursor in the mevalonate pathway. DL-Mevalonolactone is orally active against HMGCR mutation and statin caused myopathy . DL-Mevalonolactone induces inflammation and oxidative stress response with decreased mitochondrial membrane potential (MMP) and induces mitochondrial swelling ^[2][4].

HY-14925

Lapaquistat 2 Publications Verification T-91485	Natural Products Classification of Application Fields Metabolic Disease Endogenous metabolite Disease Research Fields Source Classification	Endogenous Metabolite Drug Metabolite
Lapaquistat (T-91485), a cholesterol biosynthesis inhibitor, is the active metabolite of Lapaquistat acetate (HY-16274). Lapaquistat can decrease statin-induced myotoxicity in lipid-lowering therapy .

HY-135700

Mevalonolactone	Structural Classification Microorganisms Other Phenylpropanoids Phenylpropanoids Source Classification	Calcineurin Ras HMG-CoA Reductase (HMGCR)
Mevalonolactone is an intermediate metabolite in the eukaryotic mevalonate pathway, serving as the stable δ-lactone form of mevalonate with oral activity. Mevalonolactone exhibits binding affinity for ZNF384 (K_a = 12.6 μM) and inhibitory activity against aconitase (aconitase). Mevalonolactone promotes the nuclear localization of ZNF384 and enhances its binding to the GGPPS promoter. Mevalonolactone induces insulin resistance, disrupts glucose and lipid metabolism, enhances the isoprenylation of K-Ras, and inhibits the activation of the insulin signaling pathway. Mevalonolactone inhibits polypeptide synthesis of HMG-CoA reductase in isolated rat hepatocytes, promotes its degradation, and reduces its enzymatic activity. Mevalonolactone impairs mitochondrial function in rat brains. Mevalonolactone promotes the development of metabolically unhealthy obesity. Mevalonolactone can be used in research related to metabolically abnormal obesity, mevalonic aciduria, HMGCR-related limb-girdle myopathy, and statin-induced myopathy .

HY-107855R

DL-Mevalonolactone (Standard) (±)-Mevalonolactone (Standard); Mevalolactone (Standard)	Structural Classification Natural Products Endogenous metabolite Source Classification	Endogenous Metabolite Reference Standards
DL-Mevalonolactone (Standard) is the analytical standard of DL-Mevalonolactone. This product is intended for research and analytical applications. DL-Mevalonolactone ((±)-Mevalonolactone;Mevalolactone) is the δ-lactone form of mevalonic acid, a precursor in the mevalonate pathway. DL-Mevalonolactone is orally active against HMGCR mutation and statin caused myopathy . DL-Mevalonolactone induces inflammation and oxidative stress response with decreased mitochondrial membrane potential (MMP) and induces mitochondrial swelling .

Cat. No.	Product Name	Chemical Structure

HY-138166S

Rosuvastatin lactone-d6
Rosuvastatin lactone-d₆ is the deuterium labeled Rosuvastatin lactone. Rosuvastatin lactone is a metabolite of Rosuvastatin (HY-17504A), a statin lipid-lowering agent and HMG-CoA inhibitor. Rosuvastatin lactone exhibits endothelium-independent and HMG-CoA reductase-independent vasorelaxant activity in rat aortic rings, and its vasorelaxant effect is jointly mediated by NO produced by inducible nitric oxide synthase (iNOS) located in vascular smooth muscle and activation of potassium channels. Rosuvastatin lactone itself has no lipid-lowering effect .

Rosuvastatin lactone-d6

Rosuvastatin lactone-d₆ is the deuterium labeled Rosuvastatin lactone. Rosuvastatin lactone is a metabolite of Rosuvastatin (HY-17504A), a statin lipid-lowering agent and HMG-CoA inhibitor. Rosuvastatin lactone exhibits endothelium-independent and HMG-CoA reductase-independent vasorelaxant activity in rat aortic rings, and its vasorelaxant effect is jointly mediated by NO produced by inducible nitric oxide synthase (iNOS) located in vascular smooth muscle and activation of potassium channels. Rosuvastatin lactone itself has no lipid-lowering effect .

HY-109523S

Cerivastatin-d3 sodium
Cerivastatin-d₃ sodium is deuterated labeled Cerivastatin sodium (HY-109523). Cerivastatin sodium is a synthetic lipid-lowering agent and a highly potent, well-tolerated and orally active HMG-CoA reductase inhibitor, with a Ki of 1.3 nM/L. Cerivastatin sodium reduces low-density lipoprotein cholesterol levels. Cerivastatin sodium also inhibits proliferation and invasiveness of MDA-MB-231 cells, mainly by RhoA inhibition, and has anti-cancer effect .

Cerivastatin-d3 sodium

Cerivastatin-d₃ sodium is deuterated labeled Cerivastatin sodium (HY-109523). Cerivastatin sodium is a synthetic lipid-lowering agent and a highly potent, well-tolerated and orally active HMG-CoA reductase inhibitor, with a Ki of 1.3 nM/L. Cerivastatin sodium reduces low-density lipoprotein cholesterol levels. Cerivastatin sodium also inhibits proliferation and invasiveness of MDA-MB-231 cells, mainly by RhoA inhibition, and has anti-cancer effect .

HY-W752587

DL-Mevalonolactone-d4
DL-Mevalonolactone-d₄ ( (±)-Mevalonolactone-d₄) is the deuterium labeled DL-Mevalonolactone (HY-107855). DL-Mevalonolactone ((±)-Mevalonolactone;Mevalolactone) is the δ-lactone form of mevalonic acid, a precursor in the mevalonate pathway. DL-Mevalonolactone is orally active against HMGCR mutation and statin caused myopathy . DL-Mevalonolactone induces inflammation and oxidative stress response with decreased mitochondrial membrane potential (MMP) and induces mitochondrial swelling .

DL-Mevalonolactone-d4

DL-Mevalonolactone-d₄ ( (±)-Mevalonolactone-d₄) is the deuterium labeled DL-Mevalonolactone (HY-107855). DL-Mevalonolactone ((±)-Mevalonolactone;Mevalolactone) is the δ-lactone form of mevalonic acid, a precursor in the mevalonate pathway. DL-Mevalonolactone is orally active against HMGCR mutation and statin caused myopathy . DL-Mevalonolactone induces inflammation and oxidative stress response with decreased mitochondrial membrane potential (MMP) and induces mitochondrial swelling .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks